Microvascular hemodynamics and speech function in adults at risk for alzheimer's disease

Active Grant Awarded Last action

Award ID
R15AG101712
Recipient
Awarding agency
Obligated
$624,208

Award facts

Assistance listing
93.866 Aging Research
Completion date 16% complete
Place of performance
Charlestown, MA 02129, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded The MGH Institute of Health Professions, Inc. $624,208 on May 26, 2026 under the Aging Research program (CFDA 93.866), Grant R15AG101712. The award funds a study of how speech motor control relates to cerebral microvascular physiology in adults aged 60-80 with and without the APOE-E4 allele, a genetic risk factor for Alzheimer's disease. Investigators will collect noninvasive MRI data alongside detailed speech samples. Multi-delay arterial spin labeling MRI will quantify cerebral blood flow and arterial transit time in brain regions supporting speech motor function, and acoustic and kinematic speech measures will capture speech motor control. The stated objective is to identify individuals at elevated risk for Alzheimer's disease by examining how these hemodynamic and speech measures interact.

The period of performance ends May 31, 2029. Place of performance is Charlestown, MA 02129, USA. The obligated amount is $624,208.

The program funds biomedical and behavioral research and training in aging, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
Impaired microvascular function is increasingly recognized as a key contributor to alzheimer's disease (ad)- related neurodegeneration. Although apolipoprotein E Ε4 (APOE-Ε4) is a well-established genetic risk factor for both ad and cerebrovascular disease, the mechanistic relationships between APOE-Ε4 status, cerebral hemodynamics, and cognitive-motor function remain poorly understood. This study aims to examine how speech motor control, captured through acoustic and kinematic measures, relates to cerebral microvascular physiology in individuals stratified by genetic risk for ad. There is growing evidence that microvascular dysregulation emerges during the preclinical stages of ad, preceding the accumulation of amyloid-Β plaques and TAU tangles. Our previous work has shown that speech motor control metrics are sensitive to early neurodegenerative changes, highlighting their potential as scalable, behaviorally grounded biomarkers. Given that both cerebral hemodynamic measures and speech features independently show promise in detecting early neurodegeneration, we propose to investigate their interaction as a complementary and ecologically valid approach to identifying individuals at elevated risk for ad. Speech production is among the most complex human motor behaviors, requiring the integration of cognitive, sensorimotor, and neuromuscular processes, all of which are affected in ad. In this project, we will collect noninvasive magnetic resonance imaging (MRI) data alongside detailed speech samples in a well-characterized cohort of older adults (aged 60-80) with and without the APOE- Ε4 allele. Microvascular physiology will be assessed using multi-delay arterial spin labeling (ASL) MRI to quantify cerebral blood flow (CBF) and arterial transit time (ATT) in brain regions supporting speech motor function. Speech motor control will be evaluated using acoustic and kinematic features. We hypothesize that (1) objective speech acoustic and kinematic features will distinguish APOE-Ε4 carriers from non-carriers with high classification accuracy and will outperform cognitive scores in identifying APOE-Ε4 status; (2) compared to non- carriers, APOE-Ε4 carriers will exhibit reduced CBF and ATT in brain regions supporting speech motor function, reflecting impaired neurovascular regulation; and (3) hemodynamic alterations in speech motor regions will mediate the relationship between speech performance and cognitive function in APOE-Ε4 carriers, offering a mechanistic explanation for how vascular dysfunction contributes to early behavioral markers of ad risk. The findings from this research will advance our understanding of how genetic risk for ad influences cerebral microvascular function and its downstream impact on speech motor control. This work will also evaluate the potential of speech-based assessments as low-burden, objective tools for early detection and monitoring of ad progression. By integrating neuroimaging and speech biomarkers, this project aims to inform the development of more sensitive and accessible diagnostic strategies that can be incorporated into clinical and research settings to support timely intervention and improved disease tracking.

Quick answers

Who received award R15AG101712?

R15AG101712 was awarded to The MGH Institute Of Health Professions, Inc. by National Institute on Aging (National Institutes of Health) on May 26, 2026.

How much is award R15AG101712 worth?

$624,208 has been obligated on R15AG101712.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award